Article
Alabama Peptide Enforcement Action 2026: What Every NP, PA, MD, and DO Needs to Know
In a notice published in May 2026 and reported by WSFA on May 26, the Alabama Board of Medical Examiners barred physicians from compounding, administering, or dispensing non-FDA-approved or research-grade peptides. It also said CNMs, CRNPs, and PAs have no authority to prescribe, administer, advise on, or dispense them. The notice does not bar FDA-approved drugs or peptides lawfully compounded under section 503A by a licensed pharmacy.
The Board's language reaches past the prescription pad to advising, recommending, and supplying.
An April 2026 preprint by Mendias and Awan analyzed 6,441 independently tested research-grade peptide samples. It found that 41.6% failed even the looser purity and dose standards applied to 503A compounded drugs, and 71.1% failed the standards applied to FDA-approved manufactured drugs. One in ten TB-500 samples and nearly one in ten CJC-1295 samples did not contain the stated peptide. The authors note the dataset is voluntary submissions, so it likely understates the problem.
Why does this matter right now?
Alabama is not the only state on record. Connecticut's Attorney General has sent warning letters and cease and desist letters to weight-loss clinics and med spas over their marketing of compounded GLP-1 drugs, and the Ohio Board of Pharmacy has summarily suspended a clinic's license. If you manage a multi-state longevity practice, work in regenerative medicine, or prescribe peptides as part of your anti-aging protocols, you need to know what Alabama's notice covers and how to tell whether your own state is moving in the same direction.
What will you learn in this article?
- What the Alabama Board's notice says and who it covers
- The legal difference between research-grade and compounded peptides
- What Ohio and Connecticut have done
- Compliance steps you can take this week
- How to read signals from your state medical board and pharmacy board
What exactly did the Alabama Board prohibit?
In May 2026, the Alabama Board of Medical Examiners published a notice to licensees on non-FDA-approved "research-grade" peptides. WSFA reported it on May 26. The notice covers physicians, PAs, CRNPs, and CNMs, and it bars every form of involvement: advising, recommending, supplying, prescribing, and administering.
The Board's own language:
"Research-grade peptides are not approved by the FDA and have not been tested, reviewed, or determined to be safe or effective for human use."
The scope is research-grade product. The notice targets substances sold for laboratory use and injected into patients. It does not address peptides compounded by a licensed pharmacy from an FDA-permitted bulk substance. Whether a compounded peptide is lawful depends on the FDA's 503A rules and your state pharmacy rules, covered below.
The sourcing rule is the operative test. The Board states that physicians must purchase all prescription products and ingredients from an entity permitted by the Alabama State Board of Pharmacy, and that everything administered or dispensed must be prescription quality. A vial from an online research chemical vendor fails on both counts.
Delegation doesn't work. A physician can't route the purchase or administration through a PA, CRNP, or CNM. No research-grade peptide sits on any formulary those clinicians are allowed to prescribe from, so they have no independent authority to do it either.
Consent forms don't help. The Board says a patient cannot waive the provider's duty of care, and a form labeling the product "research-grade" doesn't change what's in the vial or what the law allows.
What happened before the notice?
Two things happened before the notice. The notice itself states no reasons, so read these as background and not as the Board's motive.
1. What changed when the GLP-1 shortage ended?
Semaglutide injection went on the FDA’s drug shortage list in 2022, and tirzepatide injection followed on December 15, 2022. Under sections 503A and 503B of the FD&C Act, a drug on that list can be compounded even though it is essentially a copy of an approved product. That provision let longevity clinics and telehealth platforms sell compounded GLP-1s at a fraction of brand pricing.
The window closed in two steps. On December 19, 2024, the FDA issued a declaratory order finding the tirzepatide shortage resolved, with compounding to stop by February 18, 2025, for 503A pharmacies and March 19, 2025, for 503B facilities. On February 21, 2025, it did the same for semaglutide, with deadlines of April 22 and May 22, 2025. The Outsourcing Facilities Association sued over both orders and lost its injunction bids.
Demand did not go away when the legal basis did. Two records show what happened next.
In September 2025, the FDA sent warning letters to telehealth companies, including Hims & Hers, over how they marketed compounded GLP-1 drugs, followed by 30 more on March 12, 2026. The agency has also sent letters directly to online peptide vendors selling semaglutide and tirzepatide labeled for research use, including five in August 2026 covering semaglutide, tirzepatide, retatrutide, and tesamorelin.
The April 2026 Mendias and Awan preprint found semaglutide and tirzepatide among the most heavily tested compounds in its gray-market dataset, with tirzepatide samples failing manufactured-drug dose standards 86% of the time.
2. Why did the FDA move 19 peptides to Category 2?
On September 29, 2023, the FDA added 19 peptide bulk drug substances to Category 2 of its interim 503A policy, the list of substances that present significant safety risks and can't be compounded. The FDA's reasoning, published on its Category 2 page, cited immunogenicity risk, peptide-related impurities, API characterization problems, and limited or no human safety data. BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon, GHK-Cu (injectable), LL-37, Dihexa, DSIP, Melanotan II, and PEG-MGF were among them.
The list has shrunk twice since. Five substances came off in September 2024. Twelve more were removed effective April 22, 2026, after the FDA's April 15 update announced the nominations had been withdrawn. The FDA page notes that a substance can present a safety risk and still not appear in Category 2 for exactly that reason. Removal from Category 2 is not placement in Category 1, and none of the 12 has been added to the 503A bulks list as of this writing.
The 2023 placement gave state boards a federal determination to point to: these substances couldn't be lawfully compounded. That basis is narrower now than it was in 2025. Alabama's notice is written around research-grade sourcing and does not list peptides by name.
What is the legal difference between research-grade and compounded peptides?
The distinction between research-grade and compounded peptides determines whether the product can be lawfully used.
What are research-grade peptides?
Research-grade peptides are manufactured for laboratory and research use. They are not intended for human injection.
| Attribute | Details |
|---|---|
| Manufacturing | No FDA oversight; minimal quality controls |
| Purity standards | No industry standard; highly variable |
| Certificate of analysis | Not required; often unavailable |
| Labeling | Typically labeled "not for human consumption" or "research use only" |
| Sourcing | Often overseas; minimal chain-of-custody documentation |
| Testing data | Limited to none; purity verified only by buyer request |
| Common suppliers | Online vendors, research chemical suppliers, gray-market ingredient distributors |
| What's inside | In the April 2026 Mendias and Awan analysis of 6,441 independently tested samples, 41.6% failed 503A purity and dose standards. |
The label on the vial does not change what's inside or what the law allows. A research-grade peptide administered to a patient is an unapproved drug administered to a patient, whatever the label says.
The FDA's August 2026 warning letters to online peptide sellers show its position. The agency looked past "research use only" and "not for human consumption" labels to how the products were marketed, and treated them as unapproved new drugs for human use.
What are compounded peptides?
Compounded peptides are made by licensed pharmacies from FDA-permitted bulk substances to fill patient-specific prescriptions.
| Attribute | Details |
|---|---|
| Manufacturing | 503A pharmacies or 503B outsourcing facilities; documented quality controls |
| Purity standards | Documented purity and sterility requirements |
| Certificate of analysis | Documents purity %, testing date, and impurity limits for the lot |
| Labeling | Labeled with patient name, pharmacy license, expiration date |
| Sourcing | FDA-registered bulk substance manufacturers |
| Testing data | Documented; tested before release to the practitioner |
| Common suppliers | Licensed 503A or 503B compounding pharmacies |
| What's inside | Pharmaceutical-grade bulk substance; documented purity |
Under section 503A, a compounded peptide is lawful only if all four of these are true:
- The bulk substance meets a USP or NF monograph, is a component of an FDA-approved drug, or appears on the 503A bulks list.
- The bulk substance comes from an FDA-registered manufacturer with a valid certificate of analysis.
- The compounding pharmacy is properly state-licensed.
- A valid patient-specific prescription exists.
Category 1 is not an approved-for-compounding list. Under the FDA's interim policy, it means the FDA does not intend to take action against compounding with that substance while it evaluates the nomination for the 503A bulk list. It is enforcement discretion. It is not authorization.
Why do courts and regulators care about the distinction?
The FDA treats marketing as evidence of intended use. In its August 24, 2026 warning letters to five online peptide sellers, the FDA found that the sellers' websites showed the products were intended as drugs for human use, despite "research use only" labeling, and cited them for selling unapproved new drugs.
State boards hold the licensee responsible. Alabama's Board has said that consent forms calling a product "research-grade" do not mitigate or eliminate the provider's professional or legal liability, and that a patient cannot waive the provider's duty of care.
Civil and criminal exposure follows the same logic. A patient harmed by a research-grade peptide can sue the prescriber who administered it, and a consent form doesn't remove that liability. In serious cases, practitioners who distribute unapproved drugs can face federal criminal charges.
How do research-grade and compounded peptides compare?
| Factor | Research-grade peptides | Compounded peptides (503A) |
|---|---|---|
| Intended use | Laboratory only | Patient-specific prescription |
| Manufacturing oversight | None | 503A pharmacy or 503B facility |
| Quality standard | No CoA required | Documented purity and sterility standard |
| Sourcing documentation | Minimal; often overseas | FDA-registered bulk manufacturer |
| Prescriber liability | Not reduced by a consent form (Alabama Board notice) | Prescriber remains responsible for a valid patient-specific prescription |
| Legal status for injection | Unapproved new drug under federal law when marketed for human use, whatever the label says | Permitted only if the bulk substance meets a USP or NF monograph, is a component of an FDA-approved drug, or is on the 503A bulks list |
| Patient safety data | Minimal or none | Depends on the substance; many compounded peptides have limited human data |
| "Not for human use" label | Not a legal defense | Not labeled this way |
| Regulatory risk | Board may discipline (Alabama Board notice) | Depends on 503A eligibility and state pharmacy rules |
If you're using research-grade peptides on patients, you're administering an unapproved new drug under federal law, whatever state you practice in. If you're using compounded peptides, you're operating legally only if the bulk substance qualifies under 503A and the pharmacy is licensed. Substances in Category 2 cannot be compounded. Substances removed from Category 2 but not yet added to the bulk list have no federal safe harbor.
How are other states responding?
Other states have also acted: Ohio through its Board of Pharmacy, and Connecticut through its Attorney General.
What did Ohio's Board of Pharmacy do?
The Ohio Board of Pharmacy issued a summary suspension order against a clinic offering peptide therapies. A summary suspension takes effect immediately, before a hearing.
The order shows how the Board works. It inspects clinics as licensed terminal distributors, treats research-grade product from an unlicensed seller as adulterated and misbranded drugs under Ohio Revised Code 3715.52 and 4729.51, and uses summary suspension under 4729.571 when it finds them. This is a licensing action against a licensee. Ohio has not passed a statute naming research peptides.
What has Connecticut's Attorney General done about compounded GLP-1s?
Connecticut's record is about compounded GLP-1 drugs. We did not find a Connecticut Attorney General notice on research peptides such as BPC-157.
On May 21, 2025, Attorney General William Tong sent a letter to Connecticut weight-loss clinics and med spas warning that advertising and selling compounded GLP-1 drugs may violate the Connecticut Unfair Trade Practices Act. On December 3, 2025, his office announced cease and desist letters to weight-loss spas in Avon, Brookfield, and Danbury that were still advertising compounded semaglutide or tirzepatide. The same release says the office is investigating a trade platform that had facilitated sales of "research grade" GLP-1s to U.S. consumers.
Connecticut used its consumer protection statute. That means a state attorney general can act on drug marketing without a medical board or pharmacy board order.
Where does enforcement stand now?
As of October 2026:
- Alabama: Board of Medical Examiners notice to licensees, published May 2026
- Ohio: Board of Pharmacy summary suspension of a clinic
- Connecticut: Attorney General warning letters and cease and desist letters on compounded GLP-1 marketing
No regulator has published a timeline for which states act next. Check your own state medical board and pharmacy board for notices on peptides, and read them before your next prescription.
Are state attorneys general coordinating?
On GLP-1s, yes. In February 2025, a bipartisan coalition of 38 state and territory attorneys general wrote to the FDA asking it to act against counterfeit GLP-1 drugs and against online sellers marketing GLP-1 ingredients as research-only, and to work with state pharmacy boards on oversight of compounding. The Connecticut release linked above describes the letter.
What can you do now? A compliance framework
If you prescribe peptides, these four steps reduce your regulatory risk.
Step 1: audit your current peptide sources this week
For every peptide you currently prescribe or administer:
- Identify the source pharmacy: name, state, and license number.
- Verify pharmacy licensing. Call your state pharmacy board and ask, "Is this pharmacy a licensed 503A or 503B compounding facility?" Confirm any FDA registration yourself. Don't rely on the pharmacy's own description.
- Verify the bulk substance qualifies under 503A. Ask the pharmacy, "Does the bulk substance for this peptide meet a USP or NF monograph, is it a component of an FDA-approved drug, or is it on the 503A bulks list?" Cross-check the FDA's 503A bulk drug substances page and Category 2 list. Category 1 status alone is not authorization. If the pharmacy says "research-grade" or "not FDA-approved," stop using it.
- Request a certificate of analysis. It should show purity %, testing date, and impurity limits. Ask for a recent, lot-matched CoA. If the pharmacy can't provide one, stop using it.
- Document everything. Keep copies of the license verification in your records and the CoA for each lot with the patient chart. This is what you will be asked for in an audit.
Stop using a pharmacy if you see any of these:
- It won't provide a pharmacy license number
- It can't provide a certificate of analysis
- The CoA shows "research use only" or "not for human injection"
- It says the product is "not FDA approved but safe because low dose"
- It can't verify that the bulk source is an FDA-registered facility
- It is based overseas with no U.S. licensing
- It offers bulk-order pricing discounts, which suggests compounding that is not patient-specific
Step 2: document informed consent before the next injection
Consent does not make a research-grade product lawful. For a lawfully compounded peptide, your consent documentation should show that:
- The patient understands the compounded peptide is not FDA-approved
- The patient understands adverse events are not tracked nationally
- The patient understands known risks (immunogenicity, off-target effects, reactions to compounding impurities)
- The patient understands unknown risks (limited human data for many peptides)
- The prescriber signed and dated the form, in addition to the patient
- The discussion happened before the injection
Template language you can use:
"I discussed the regulatory status, known risks, and potential benefits of [peptide name] with [patient name] on [date]. The patient understands this medication is not FDA-approved and that adverse events may occur. [Patient name] consented to proceed with administration. Alternative treatments discussed: [list alternatives]. Prescriber: [signature], [date]."
Step 3: track and report adverse events
- Document in the patient chart what happened, when, and how severe it was.
- Report it to the compounding pharmacy.
- Report serious events to FDA MedWatch.
- Notify your malpractice carrier early.
Document everything, including mild events.
Step 4: Monitor state regulatory changes quarterly
Set a quarterly reminder to:
- Read your state medical board newsletter (most boards have an email list)
- Check your state pharmacy board for compounding updates
- Check the FDA's PCAC page and the Federal Register for 503A bulk list decisions
What questions are practitioners asking right now?
If I'm in Arizona, do I need to worry about Alabama?
Yes. Arizona is a state with no peptide-specific board notice that we found, but three things still apply.
If you treat patients in Alabama, Ohio, or Connecticut, you're subject to those states' rules. Telehealth counts: when your patient is located in one of those states, you may face liability there.
Check your malpractice coverage. Ask your carrier in writing whether your policy covers claims from administering or dispensing unapproved or compounded peptides, and in which states.
A state with no notice today can publish one tomorrow. Don't treat your state's current position as permanent.
Can a consent form that calls the product research-grade protect me?
No. The Board addressed this directly:
"Patient consent forms purporting to identify a product as 'research-grade' are ineffective and do not mitigate or eliminate the health care provider's professional or legal liability."
The notice also states that a provider cannot require or permit a patient to waive the provider's duty of care or the provider's obligation to follow the law. The Board's test is what happens to the patient. A product labeled "research use only" that is administered to a patient is a non-FDA-approved peptide administered to a patient.
How have peptide compounding rules changed since 2023?
Two separate changes are often mixed up.
GLP-1s. Starting in 2022, semaglutide and tirzepatide were on the FDA's drug shortage list, which allowed pharmacies to compound copies. The FDA found the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025, and the compounding windows closed in 2025. Neither drug was ever in Category 2.
Category 2 peptides. In September 2023, the FDA placed 19 peptide bulk substances, including BPC-157 and TB-500, in Category 2. Five came off in September 2024 and twelve more on April 22, 2026. Coming off Category 2 does not make a substance eligible for compounding.
What a 503A pharmacy can use now is a bulk substance that meets a USP or NF monograph, is a component of an FDA-approved drug, or is on the 503A bulks list, made by an FDA-registered manufacturer and supplied with a certificate of analysis. Category 1 is not an approval list. Ask the pharmacy which of these routes applies to each peptide before you prescribe it.
The FDA panel voted for BPC-157 in July. Is it legal to compound now?
No. Here is where the process stands.
February 27, 2026: HHS Secretary Kennedy said on a podcast that most of the Category 2 peptides would be moved back toward Category 1. This was a remark, not a formal agency announcement.
April 15, 2026: The FDA published a 503A categories update removing 12 peptides from Category 2 because the nominations were withdrawn, effective April 22. A Federal Register notice the next day scheduled seven of them for a Pharmacy Compounding Advisory Committee (PCAC) meeting in July and the remaining five for a session before the end of February 2027.
July 23 and 24, 2026: PCAC voted to recommend six of the seven for the 503A bulks list: BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon. Emideltide (DSIP) was rejected. The FDA's own review staff had recommended against all seven.
October 2026: The FDA has not issued a final rule. PCAC is advisory. Until the FDA adds a substance to the 503A bulk list through rulemaking, a pharmacy compounding it has no federal authorization, and a prescriber ordering it is prescribing an unapproved drug from a non-permitted process.
Do not prescribe on the strength of a vote or a press statement. Watch the Federal Register, then check whether your state pharmacy board follows.
I prescribe GLP-1s through telemedicine. Am I at risk?
It depends on what you're prescribing.
Brand-name tirzepatide (Zepbound, Mounjaro) or semaglutide (Wegovy, Ozempic): FDA-approved, brand-name GLP-1s are outside these peptide notices; normal prescribing rules still apply.
Compounded tirzepatide or semaglutide: the shortage basis for compounding copies ended in 2025. Section 503A bars a pharmacy from regularly compounding a drug that is essentially a copy of a commercially available product.
Imported or research-labeled GLP-1s: these are unapproved drugs under federal law, and they are the products the FDA's vendor warning letters and the Connecticut Attorney General's investigation address.
Should I close my peptide practice or pivot to something else?
There are three paths.
Option 1: stay in peptides that qualify under 503A. Offer only peptides whose bulk substance meets a USP or NF monograph, is a component of an FDA-approved drug, or is on the 503A bulks list. The menu is shorter. The business model stays similar.
Option 2: move to adjacent services. Exit peptides and focus on medical weight loss with FDA-approved GLP-1 drugs, hormone therapy, or oral compounds. Each has its own rules. Testosterone, for example, is a Schedule III controlled substance.
Option 3: exit the category. Phase out peptide offerings and build the practice around other services.
Which path fits depends on your state and your patients; review it with counsel.
What happens next? Regulatory signals to watch
Two things will tell you where peptide rules are heading: the federal PCAC process and signals from your own state.
Where does the PCAC review stand?
The FDA's Pharmacy Compounding Advisory Committee advises the agency on which bulk substances belong on the 503A bulks list. The FAQ above has the full sequence.
- April 15, 2026: the FDA removed 12 peptides from Category 2, effective April 22
- April 16, 2026: a Federal Register notice scheduled seven of them for review in July and five more (GHK-Cu, Melanotan II, LL-37, Dihexa, and PEG-MGF) for a meeting before the end of February 2027
- July 23 and 24, 2026: PCAC recommended six of the seven for the 503A bulks list and rejected emideltide (DSIP)
PCAC votes are advisory. A substance joins the 503A bulks list only through FDA rulemaking, and the FDA has not issued a final rule. If a rule is published in the Federal Register, those peptides could become lawful to compound federally. State boards may still add restrictions, so a federal rule doesn't guarantee state-level legality.
Watch the Federal Register and the FDA's PCAC page. When the FDA publishes a rule, read your state pharmacy board's response.
What should you watch in your own state?
Signals worth watching on your board's site:
- A guidance letter or notice on peptides from the state medical board
- Pharmacy board orders against compounding pharmacies or clinics in your state
- Attorney general press releases that mention peptides or compounded GLP-1s
- Legislative hearings on compounding pharmacy regulation
If you see one, review your sourcing with counsel.
What should you do this month?
This week
- Identify every peptide in your practice by source: research-grade or compounded.
- Call your pharmacy and ask, "What is your state license and FDA registration status? Can you provide a CoA for every lot?"
- If you can't get clear answers, stop using that pharmacy
- Update your informed consent documentation for all ongoing patients
- Sign up for your state medical board newsletter and pharmacy board updates
Within 30 days
- Decide whether to stay in peptides that qualify under 503A or exit the category.
- If you stay, confirm with your pharmacy which peptides qualify and by which 503A route.
- If you exit, plan the transition for current patients
- Consult a healthcare attorney in your state about multi-state exposure and liability
About the author
How does Scriptura support prescribing decisions?
If you manage a multi-state practice or have exposure in Alabama, Ohio, or Connecticut, book a demo to see how Scriptura's clinical decision support works for prescribers. Clinicians verify their license before platform access.
Educational and regulatory information only
This article is for educational and regulatory information only. It is not legal advice and does not create an attorney-client relationship. Rules change. Confirm current requirements with your state boards and a healthcare attorney licensed in your state before acting.
